Insmed Incorporated (INSM)

US — Healthcare Sector
Peers: ASND  APLS  BGNE  AKRO  BPMC  CERE  RNA  RVMD  DAWN  SWTX  KROS  JANX  FENC  EWTX  HRMY  HALO  AGIO  RARE 

Automate Your Wheel Strategy on INSM

With Tiblio's Option Bot, you can configure your own wheel strategy including INSM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol INSM
  • Rev/Share 2.1068
  • Book/Share 0.5483
  • PB 133.2935
  • Debt/Equity 11.5307
  • CurrentRatio 5.8633
  • ROIC -0.5609

 

  • MktCap 13310718120.0
  • FreeCF/Share -4.3639
  • PFCF -16.865
  • PE -13.0442
  • Debt/Assets 0.6342
  • DivYield 0
  • ROE -4.4698

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation INSM Jefferies -- Buy -- $105 May 13, 2025
Initiation INSM RBC Capital Mkts -- Outperform -- $100 Feb. 25, 2025

News

Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates
INSM
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Neutral

INSM posts wider-than-expected loss in the first quarter. It reiterates the 2025 sales outlook for Arikayce in the range of $405-$425 million.

Read More
image for news Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates
Insmed Incorporated (INSM) Q1 2025 Earnings Call Transcript
INSM
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral

Insmed Incorporated (NASDAQ:INSM ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Bryan Dunn - Investor Relations Will Lewis - Chair and Chief Executive Officer Sara Bonstein - Chief Financial Officer Martina Flammer - Chief Medical Officer Conference Call Participants Andrea Newkirk - Goldman Sachs Jason Zemansky - Bank of America Nick Lenard - JPMorgan Joe Schwartz - Leerink Partners Ritu Baral - TD Cowen Jennifer Kim - Cantor Fitzgerald Liisa Bayko - Evercore Graig Suvannavejh - Mizuho Securities Leonid Timashev - RBC Nicole Germino - Truist Securities Maxwell Skor - Morgan Stanley Trung Huynh …

Read More
image for news Insmed Incorporated (INSM) Q1 2025 Earnings Call Transcript
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates
INSM
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative

Insmed (INSM) came out with a quarterly loss of $1.42 per share versus the Zacks Consensus Estimate of a loss of $1.36. This compares to loss of $1.06 per share a year ago.

Read More
image for news Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates
Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update
INSM
Published: May 08, 2025 by: PRNewsWire
Sentiment: Neutral

—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $92.8 Million for the First Quarter of 2025, Reflecting 23% Growth Over the First Quarter of 2024— —NDA for Brensocatib in Patients with Bronchiectasis Remains on Track, with a PDUFA Target Action Date of August 12, 2025— —Phase 2b Study of TPIP in Patients with PAH Completed; Topline Data Expected in June 2025— —Enrollment Completed for Phase 2b BiRCh Study of Brensocatib in Patients with CRSsNP; Topline Data Anticipated By the End of 2025— —MAA Filings for Brensocatib in Patients with Bronchiectasis Accepted by EMA and MHRA— —Company Reiterates 2025 Global ARIKAYCE …

Read More
image for news Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update
Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline
INSM
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
ACLX, BSX, DHR, GKOS, INSM, ISRG, LLY, RDNT, UNH, VRTX
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Positive

Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts.

Read More
image for news Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Insmed: Poised For Transformation Beyond ARIKAYCE
INSM
Published: April 25, 2025 by: Seeking Alpha
Sentiment: Positive

Insmed's future hinges on the development and launch of its pipeline, particularly brensocatib, despite current financial losses due to strategic investments. Brensocatib shows promising Phase 3 results for non-cystic fibrosis bronchiectasis, with a potential FDA approval by August 2025, highlighting a significant market opportunity. Insmed's diversified pipeline, including TPIP and INS1201, reduces reliance on a single product and enhances long-term growth prospects.

Read More
image for news Insmed: Poised For Transformation Beyond ARIKAYCE
Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference
INSM
Published: March 25, 2025 by: PRNewsWire
Sentiment: Neutral

—New Analyses from the Phase 3 ASPEN Study Examining Efficacy and Safety of Brensocatib Across a Variety of Prespecified Subgroups— —Data from ASPEN Post-hoc Analysis Evaluating Changes in Lung Function in Bronchiectasis Patients Who Did or Did Not Experience Pulmonary Exacerbations in the Trial— — Data on Health Status Improvements Over Time Following Culture Conversion in Patients with Mycobacterium Avium Complex (MAC) Lung Disease— BRIDGEWATER, N.J. , March 25, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that …

Read More
image for news Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference
Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis
INSM
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral

—FDA Reaffirms Application is Under Priority Review with a PDUFA Target Action Date of August 12, 2025— BRIDGEWATER, N.J. , Feb. 24, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it does not currently plan to hold an advisory committee meeting to discuss the New Drug Application (NDA) for brensocatib for patients with non-cystic fibrosis bronchiectasis.

Read More
image for news Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis
Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript
INSM
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Neutral

Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript

Read More
image for news Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript
Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update
INSM
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral

—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $104.4 Million for Fourth-Quarter and $363.7 Million for Full-Year 2024, Reflecting 19% Annual Growth and Exceeding the Upper End of Full-Year 2024 Guidance Range— —Company Reiterates 2025 Global ARIKAYCE Revenue Guidance of $405 Million to $425 Million, Reflecting Double-Digit Growth Compared to 2024— —NDA for Brensocatib in Patients with Bronchiectasis Accepted by FDA and Granted Priority Review with a PDUFA Target Action Date of August 12, 2025— —Phase 2b Study of TPIP in Patients with PAH, Phase 2b BiRCh Study of Brensocatib in Patients with CRSsNP, and Phase 3 ENCORE Study of …

Read More
image for news Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update
Insmed To Present at March 2025 Investor Conferences
INSM
Published: February 11, 2025 by: PRNewsWire
Sentiment: Neutral

BRIDGEWATER, N.J. , Feb. 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: 45th Annual TD Cowen Healthcare Conference in Boston, on Monday, March 3, 2025, at 9:10 a.m.

Read More
image for news Insmed To Present at March 2025 Investor Conferences

About Insmed Incorporated (INSM)

  • IPO Date 2000-06-01
  • Website https://www.insmed.com
  • Industry Medical - Pharmaceuticals
  • CEO Mr. William H. Lewis J.D., M.B.A.
  • Employees 1271

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.